Pegcetacoplan Research

Yandian F, Fervenza FC, Caravaca-Fontán F

Complement 3 glomerulopathy is a rare and highly heterogeneous complement-mediated kidney disease characterized by the aberrant deposition of complement components in the glomeruli, triggering inflammation and contributing to progressive kidney function impairment. Despite recent advancements in ...

Orland M, Gurnari C, Sanikommu S, Maciejewski J, Dingli D

Limited published data exist on switching therapy from pegcetacoplan to iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH).Three patient cases were collected from the Mayo Clinic, Cleveland Clinic, and Levine Cancer Institute.Patient 1 is a 57-year-old woman with PNH. She experi...

Java A, Subramanian A, Nester C

Overactivation of the complement system plays a role in the pathophysiology of several serious kidney diseases, such as immunoglobulin A nephropathy, complement 3 glomerulopathy, atypical hemolytic uremic syndrome, and antineutrophil cytoplasmic antibody-associated vasculitis. A key focus of rece...

Dastoor H, Khater E, Al Salam S, Holt SG

Prod'hom S, Massa H, Thumann G, Malclès A

Presbyopia, atrophic age-related macular degeneration, and thyroid eye disease are ophthalmic conditions that can significantly affect patients' vision and quality of life. In this article, we present the most recent therapeutic innovations for their management, including the myotic eye drop acec...

Kavanagh D, Ariceta G, Vivarelli M, Schaefer F, Caravaca-Fontán F, Frémeaux-Bacchi V et al.

C3 glomerulopathy (C3G) and primary (idiopathic) immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare kidney diseases characterized by dysregulation of the complement system and progressive deposition of C3 and its breakdown products in the glomeruli, ultimately leading to k...

Ueno S

Patients with paroxysmal nocturnal hemoglobinuria (PNH) experience a significant decline in quality of life (QOL) due to various symptoms and organ damage associated with intravascular hemolysis. Red blood cell transfusions and other traditional supportive therapies offer only limited symptomatic...

Bhandari SK, Lee S, Kim HJ

Dry age-related macular degeneration (AMD) is the leading cause of central vision loss among the elderly, yet no curative treatment exists. While exudative AMD can be managed with anti-vascular endothelial growth factor (VEGF) therapy, dry AMD-accounting for more than 85% of cases-progresses insi...

Ruiz-Cabello JE, Trujillo H, Cavero T, Andrés A, Praga M, Caravaca-Fontán F et al.

Recurrent C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) remain major causes of kidney allograft dysfunction and loss. Their pathogenesis involves genetic susceptibility, acquired complement dysregulation, and transplant-related trig...

Langemeijer SMC, Langereis JD, Avest MT, Duineveld C, van de Logt AE, De Kat Angelino CM et al.

Complement inhibitor pegcetacoplan binds to C3 and its activation product C3b. Pegcetacoplan has been approved for the treatment of paroxysmal nocturnal hemoglobinuria. Because pegcetacoplan exerts broad inhibition of the complement cascade its efficacy is also investigated in numerous other dise...

Panse J, Llamas JCV, Wilson K, Hakimi Z, Czech B, Kerr B et al.

This study investigated outcomes and response to pegcetacoplan in complement inhibitor naïve (CInaïve) and experienced (CIexp) PNH patients.Data were drawn from the Adelphi PNH Disease Specific Programme™, a cross-sectional survey of physicians and their patients in Canada, Franc...

Moradi S, Khajeamiri Y, Zandi S, Keramati M, Mohammadnezhad G

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, life-threatening hematologic disorder characterized by chronic hemolysis, bone marrow and organ failure, and thrombotic events. Without effective treatment, PNH can lead to severe complications, including organ damage, increased morbidity, and ...

Antonietti M, Mercado C, Smiddy WE, Schwartz SG

Intravitreal injections are standard treatment for various manifestations of age-related macular degeneration (AMD) but are associated with rare complications, including central retinal vein occlusion (CRVO). This report describes three cases of CRVO following intravitreal injections in patients ...

Rodríguez de Córdoba S, Reparaz Suevos A, González Sanz S, Fernández FJ, Vega MC, Varela EC et al.

Paroxysmal nocturnal hemoglobinuria (PNH) is treated with complement inhibitors, yet incomplete responses remain a challenge. Terminal inhibition with eculizumab prevents intravascular hemolysis but often leaves residual extravascular hemolysis, while proximal inhibitors such as pegcetacoplan mit...

Román Ortiz E, Sáez Bello M, Reparaz Suevos A, Perez Ebri M, Aguilar Bacallado F, LLopis Salvia P et al.

C3 glomerulopathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) represent a continuous spectrum of a glomerular disease driven by dysregulation of the complement and characterized by C3 deposition alone or associated with immunoglobulins. Despite the signifi...

Trivizki O, Wykoff CC, Smoor MA, Rabinovitch D, Zhou A, Cao JA et al.

Pegcetacoplan, a complement component 3 (C3) inhibitor, has recently received U.S. Food and Drug Administration approval for treating geographic atrophy (GA), an advanced stage of age-related macular degeneration (AMD). However, the limited treatment response prompts further investigations into i...

Zand L, Fervenza FC

Fakhouri F, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP et al.

C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (MPGN) generally result in glomerular C3 deposition and irreversible kidney damage. The efficacy and safety of pegcetacoplan, a C3 and C3b inhibitor, in persons with C3 glomerulopathy or primary immune-complex M...

Mirioglu S, Ozturk S

C3 glomerulopathy (C3G) is a rare kidney disease characterized by dysregulation of the alternative pathway of the complement system. Efficacy of the available treatment options is quite limited, and almost half of the patients progress to kidney failure within 10 years. Moreover, the disease is k...